Document Type : Original Articles
Authors
1
Department of Pathology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
2
Department of Pediatrics, School of Medicine, Amir al momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran.
3
Department of anatomical sciences, Faculty of medicine, Zabol University of medical sciences, Zabol, Iran.
4
Department of Pathology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran.
5
Department of plant Breeding and Biotechnology, Faculty of Agriculture, University of Zabol, Zabol, Iran.
6
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Zabol, Zabol, Iran.
7
Department of Agronomy and Plant Breeding, Faculty of Agriculture and Natural Resources, University of Mohaghegh Ardabili, Ardabil, Iran.
8
Department of Agronomy and Plant Breeding, Agriculture Institute, Research Institute of Zabol, Zabol, Iran,
10.22092/ari.2024.366319.3229
Abstract
Gastric cancer is the fourth most common cancer in the world and the second leading cause of cancer-related deaths worldwide. Gastric cancer was responsible for approximately 768,000 deaths. MicroRNAs (miRNAs), as short non-coding RNAs, undoubtedly play a central and decisive role in various types of cancer due to their interaction with target genes. Since the discovery of the identity and clinical functions of miRNAs in the past few decades, their potential as therapeutic targets in cancer research has been the focus of extensive study. The aim of this study is to investigate the role of microRNAs in gastric cancer, focusing on their expression, biogenesis, and potential as therapeutic biomarkers. MicroRNAs (miRNAs) are essential regulators of cell proliferation, signaling pathways, and the cell cycle. They can also serve as markers of metastasis in the stomach, liver, and lymph nodes, as well as indicators of response to chemotherapy in cancer patients. Several studies have shown that miRNAs in gastric cancer have been effective as biomarkers for cancer prognosis. Currently, various oncogenic clinical trials are underway, exploring the use of miRNAs in screening, diagnosis, and drug testing. However, many systematic molecular mechanisms, including a detailed investigation of miRNAs and their expression in gastric cancer, remain unknown. Therefore, in addition to presenting the updated results of recent preclinical studies, researchers have investigated the biogenesis of miRNAs and their expression in cancer cells. It is hoped that the analysis of molecular interaction effects and the identification of miRNA target molecules and signaling pathways will contribute to the prevention and treatment of this disease.
Keywords
Main Subjects
)